[Treatment of aplastic anemia with antithymocyte globulin, Lymphoser Berna].

In: [Rinsho ketsueki] The Japanese journal of clinical hematology · 1993 · vol. 34(7) , pp. 815–20 · PMID:8360986 · W2420397745
article OA: closed CC0
View on OpenAlex View on PubMed
AI-generated summary by gemini-2.5-flash-lite, 2026-06-12

Twenty-four aplastic anemia patients treated with antithymocyte globulin (ATG) and methylprednisolone showed sustained hematopoiesis improvement in 45% of cases, with ATG without thrombocyte absorption yielding better results.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Twenty-four patients with aplastic anemia (19 severe: 5 moderate) were treated with combined immunosuppression consisting of antithymocyte globulin (ATG: Lymphoser Berna, Swiss Serum and Vaccine Institute Berne) and high-dose methylprednisolone. Danazol or meptiostane was administered concurrently for at least 3 months. Three batches of ATG were used, two were not absorbed with thrombocytes and one was absorbed with thrombocytes for the prevention of thrombocytopenia. Nine of 20 evaluable patient (45%) had sustained improvement in hematopoiesis within 3 months of treatment. Nine of 14 patients (64%) showed a response to ATG without thrombocyte absorption, on the other hand, none of 6 patients responded to ATG with thrombocyte absorption. By life table analysis, the 3 year probability of survival was 81 +/- 27% after the combined immunosuppressive therapy. These results indicated that ATG therapy was very effective in Japanese patients with aplastic anemia.

My notes (saved in your browser only)

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

openalex
last seen: 2026-05-10T10:49:29.227314+00:00
License: CC0 · commercial use OK